$1.03
arrow_drop_down1.90%Key Stats | |
---|---|
Open | $1.05 |
Prev. Close | $1.05 |
EPS | -1.73 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $71.81M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 1.01 | 1.05 |
52 Week Range | 0.70 | 3.14 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.73 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147%
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update